Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2003

View Archived Issues

Beneficial effects described for NN-2211 in the treatment of type 2 diabetes

Novel 5-HT1 receptor ligands discovered by GSK researchers

AstraZeneca presents dual CCR3 modulators/histamine H1 antagonists

New 5-HT6 receptor ligands designed by Akzo Nobel scientists

Two series of carbamate-based analgesic agents newly developed at Gruenenthal

AxyS presents novel factor VIIa/factor Xa inhibitors

Novel Jak kinase inhibitors for use in inflammation and cancer

ArQule completes Cyclis acquisition

Requip sNDA for restless legs syndrome filed

Aventis and Regeneron enter global agreement for VEGF Trap

Takeda acquires Japanese rights to antiobesity drug candidate ATL-962

Private equity financing to advance development of Panvac-VF and Prostvac-VF

NIAID grant supports development of oral smallpox drug at Chimerix

Phase I trial evaluates Psoraxine for psoriasis

Antisoma acquires Cytogen's R-1549 royalty rights

Clofarabine granted fast track status for pediatric leukemia

Improved glycemic control associated with exenatide in diabetes

SBIR grant supports BioSante's oral insulin development efforts

Rexin-G designated an orphan drug for pancreatic cancer

Phase I/II trial approved to evaluate Collidem in colorectal cancer

StaphVAX immunogenicity trial successfully completed

Positive endoscopy results for NCX-4016

NDA filed for cinacalcet hydrochloride

EntreMed grants Oxford BioMedica gene rights for ophthalmic applications

Abilify sNDA approved for maintaining stability in patients with schizophrenia

Taisho discusses design and SAR of group II mGluR antagonists at ACS meeting

Inhibitors of procollagen C-endopeptidase synthesized and evaluated as potential antifibrotic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...